Other: Control ( DrugBank: - )

9 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	4
19	Lysosomal storage disease	1
67	Polycystic kidney disease	2
70	Spinal stenosis	1
75	Cushing disease	1
85	Idiopathic interstitial pneumonia	1
97	Ulcerative colitis	2
162	Pemphigoid	1
193	Prader-Willi syndrome	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02785978 (ClinicalTrials.gov)	June 2016	11/5/2016	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Parkinson Disease;Healthy Volunteers	Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion	Institut de Myologie, France	NULL	Completed	18 Years	N/A	All	30	N/A	France
2	NCT02216188 (ClinicalTrials.gov)	August 2014	12/8/2014	Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity	Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008	Parkinson's Disease	Biological: AFFITOPE® PD01A;Other: Control	Affiris AG	NULL	Completed	40 Years	68 Years	Both	28	Phase 1	Austria
3	NCT02046447 (ClinicalTrials.gov)	May 2014	23/1/2014	Neuroimaging of Dystonia	Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida	Primary Cervical Dystonia;DYT 1 Dystonia	Drug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 Dystonia	University of Florida	Bachmann Strauss Dystonia & Parkinson Foundation, Inc.	Completed	7 Years	70 Years	All	20	N/A	United States
4	NCT01568099 (ClinicalTrials.gov)	February 2012	16/3/2012	Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease	A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease	Parkinson's Disease	Biological: AFFITOPE® PD01A;Other: Control	Affiris AG	NULL	Completed	40 Years	65 Years	Both	32	Phase 1	Austria

19. Lysosomal storage disease

Clinical trials : 854 / Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00920647 (ClinicalTrials.gov)	November 18, 2009	12/6/2009	A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®	A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment	Hunter Syndrome	Other: Control;Drug: Idursulfase IT (1 mg);Drug: Idursulfase IT (10 mg);Drug: Idursulfase IT (30 mg)	Shire	NULL	Completed	3 Years	18 Years	Male	16	Phase 1/Phase 2	United States;United Kingdom

67. Polycystic kidney disease

Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04939935 (ClinicalTrials.gov)	April 2022	16/6/2021	Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)	Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): A Randomised Placebo-Controlled Trial	Autosomal Dominant Polycystic Kidney Disease	Drug: Metformin XR;Other: Control	The University of Queensland	NULL	Not yet recruiting	18 Years	70 Years	All	1164	Phase 3	Australia
2	NCT04680780 (ClinicalTrials.gov)	January 10, 2021	1/10/2020	Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	ADPKD	Other: Ketogenic diet;Other: 3-days water-fasting;Other: Control	University of Cologne	NULL	Active, not recruiting	18 Years	60 Years	All	63	N/A	Germany

70. Spinal stenosis

Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04483297 (ClinicalTrials.gov)	November 18, 2020	14/7/2020	First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)	First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery	Degenerative Spondylolisthesis;Spinal Stenosis	Drug: AK1320 MS;Other: Control	Asahi Kasei Pharma Corporation	Emergent Clinical Consulting, LLC	Recruiting	22 Years	80 Years	All	40	Phase 1	Canada

75. Cushing disease

Clinical trials : 203 / Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02889224 (ClinicalTrials.gov)	February 2012	30/8/2016	In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man	In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man	Cushing's Syndrome	Other: Obese;Procedure: Hypercortisolism;Other: Hydrocortisone;Other: Control	University Hospital, Bordeaux	NULL	Completed	18 Years	N/A	All	40	N/A	France

85. Idiopathic interstitial pneumonia

Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02135380 (ClinicalTrials.gov)	August 2014	8/5/2014	Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis	A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF).	Idiopathic Pulmonary Fibrosis	Biological: Autologous Stromal Vascular Fraction (SVF);Biological: Autologous Adipose Derived MSCs (ADMSCs);Other: Control	Kasiak Research Pvt. Ltd.	NULL	Recruiting	30 Years	70 Years	Both	60	Phase 1/Phase 2	India

97. Ulcerative colitis

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02442037 (ClinicalTrials.gov)	May 2015	6/5/2015	Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis	Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Active Ulcerative Colitis.	Ulcerative Colitis	Biological: UCMSC group;Other: Control group(Normal saline)	Affiliated Hospital to Academy of Military Medical Sciences	Ivy Institute of Stem Cells Co. Ltd	Recruiting	18 Years	65 Years	Both	30	Phase 1/Phase 2	China
2	NCT01479660 (ClinicalTrials.gov)	March 2011	22/11/2011	Role of Healthy Bacteria in Ulcerative Colitis	Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial	Ulcerative Colitis	Other: Control;Drug: Probiotic	Postgraduate Institute of Medical Education and Research	Ministry of Science and Technology, India	Recruiting	18 Years	65 Years	Both	100	Phase 4	India

162. Pemphigoid

Clinical trials : 83 / Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04563923 (ClinicalTrials.gov)	October 10, 2020	17/9/2020	Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody	Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody	Bullous Pemphigoid	Drug: Avdoralimab (IPH5401);Other: Control	Centre Hospitalier Universitaire de Nice	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	France

193. Prader-Willi syndrome

Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03081832 (ClinicalTrials.gov)	January 2017	10/3/2017	Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.	Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)	Prader-Willi Syndrome	Drug: Oxytocin;Other: Control	University Hospital, Toulouse	NULL	Completed	3 Years	4 Years	All	34	N/A	France